Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model.
Animals
Antigens, Bacterial
/ immunology
BCG Vaccine
/ immunology
Beijing
/ epidemiology
Disease Models, Animal
Glucosides
/ pharmacology
Humans
Immunization, Secondary
Lipid A
/ pharmacology
Mice
Mycobacterium tuberculosis
/ drug effects
Th1 Cells
/ immunology
Tuberculosis
/ drug therapy
Tuberculosis Vaccines
/ immunology
Vaccination
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 10 2019
29 10 2019
Historique:
received:
14
06
2019
accepted:
04
10
2019
entrez:
31
10
2019
pubmed:
31
10
2019
medline:
3
11
2020
Statut:
epublish
Résumé
Since ID93/GLA-SE was developed as a targeted BCG-prime booster vaccine, in the present study, we evaluated the protective efficacy of ID93/GLA-SE as a boost to a BCG-prime against the hypervirulent Mycobacterium tuberculosis (Mtb) K challenge to provide further information on the development and application of this vaccine candidate. Boosting BCG with the ID93/GLA-SE vaccine significantly reduced bacterial burden at 16 weeks post-challenge while the BCG vaccine alone did not confer significant protection against Mtb K. The pathological analysis of the lung from the challenged mice also showed the remarkably protective boosting effect of ID93/GLA-SE on BCG-immunised animals. Moreover, qualitative and quantitative analysis of the immune responses following ID93/GLA-SE-immunisation demonstrated that ID93/GLA-SE was able to elicit robust and sustained Th1-biased antigen-specific multifunctional CD4
Identifiants
pubmed: 31664157
doi: 10.1038/s41598-019-52146-0
pii: 10.1038/s41598-019-52146-0
pmc: PMC6820558
doi:
Substances chimiques
Antigens, Bacterial
0
BCG Vaccine
0
Glucosides
0
Lipid A
0
Tuberculosis Vaccines
0
glucopyranosyl lipid-A
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15560Subventions
Organisme : NIAID NIH HHS
ID : R01 AI125160
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007509
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : R01AI125160
Pays : International
Références
PLoS Pathog. 2019 Mar 4;15(3):e1007643
pubmed: 30830940
Clin Infect Dis. 2000 Sep;31 Suppl 3:S64-7
pubmed: 11010824
Immunology. 2013 Oct;140(2):220-31
pubmed: 23721367
Infect Immun. 2006 Apr;74(4):2392-401
pubmed: 16552069
Lancet Respir Med. 2018 Apr;6(4):287-298
pubmed: 29595510
Vaccine. 2013 Apr 19;31(17):2196-206
pubmed: 22643213
PLoS One. 2012;7(6):e39909
pubmed: 22768165
Nat Genet. 2015 Mar;47(3):242-9
pubmed: 25599400
N Engl J Med. 2018 Jul 12;379(2):138-149
pubmed: 29996082
Vaccines (Basel). 2018 May 24;6(2):
pubmed: 29795025
Infect Immun. 2008 Nov;76(11):5173-80
pubmed: 18710860
Sci Rep. 2017 Mar 08;7:44151
pubmed: 28272457
PLoS One. 2013 Dec 12;8(12):e80579
pubmed: 24349004
J Immunol. 2011 Nov 15;187(10):5402-7
pubmed: 22003199
JAMA. 1994 Mar 2;271(9):698-702
pubmed: 8309034
FASEB J. 2019 May;33(5):6483-6496
pubmed: 30753099
Vaccine. 2011 Apr 5;29(16):2902-9
pubmed: 21338678
Vaccine. 2017 Mar 14;35(12):1652-1661
pubmed: 28216183
J Immunol. 2007 Mar 15;178(6):3721-30
pubmed: 17339470
Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2301-6
pubmed: 19188599
Infect Immun. 2010 Oct;78(10):4187-94
pubmed: 20679438
PLoS Pathog. 2014 May 15;10(5):e1004099
pubmed: 24831696
J Immunol. 2010 Apr 15;184(8):4414-22
pubmed: 20212094
PLoS One. 2015 Dec 16;10(12):e0145234
pubmed: 26675186
J Infect Dis. 2011 Nov 15;204(10):1573-84
pubmed: 21933877
NPJ Vaccines. 2018 Sep 4;3:34
pubmed: 30210819
Clin Vaccine Immunol. 2011 Sep;18(9):1527-35
pubmed: 21795460
BMJ. 2014 Aug 05;349:g4643
pubmed: 25097193
Vaccine. 2016 Apr 27;34(19):2179-87
pubmed: 27005808
Lancet Infect Dis. 2010 Feb;10(2):103-11
pubmed: 20113979
J Immunol. 2004 Jun 15;172(12):7618-28
pubmed: 15187142
Microbes Infect. 2009 Nov;11(13):995-1001
pubmed: 19635582
J Immunol. 2008 Feb 1;180(3):1962-70
pubmed: 18209095
Clin Infect Dis. 2014 Feb;58(4):470-80
pubmed: 24336911
Vaccine. 2015 Jul 9;33(30):3592-9
pubmed: 26048780
Sci Rep. 2018 Oct 17;8(1):15309
pubmed: 30333506
Vaccine. 2010 Jan 22;28(4):1084-93
pubmed: 19896449
Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):8136-41
pubmed: 26080405
Infect Immun. 2005 Sep;73(9):5809-16
pubmed: 16113299
Sci Transl Med. 2010 Oct 13;2(53):53ra74
pubmed: 20944089
Int J Tuberc Lung Dis. 2001 Sep;5(9):824-30
pubmed: 11573893
Clin Vaccine Immunol. 2015 Dec 09;23(2):137-47
pubmed: 26656121
Vaccine. 2015 Nov 27;33(48):6570-8
pubmed: 26541135
J Immunol. 2012 Mar 1;188(5):2189-97
pubmed: 22291184
J Infect Dis. 2013 Apr 15;207(8):1242-52
pubmed: 22891286
N Engl J Med. 2018 Oct 25;379(17):1621-1634
pubmed: 30280651
Nat Immunol. 2007 Apr;8(4):369-77
pubmed: 17351619